United States · Investor

Royalty Pharma

Last cheque observed Aug 2026; 3 cheques on record.

Email

Growth equityDeploying now

Series B

Deploying now
50%of best year1cheques in 12 months, 3 on record
Since the last cheque85days00hrs00min00sec
Median round$270MRounds led1 of 3Sole investor1 rounds
Pitch Royalty Pharma

Royalty Pharma highlights

  1. 01

    1 cheques in the last 12 months

  2. 02

    Mostly Series B: 100% of its rounds

  3. 03

    Sole investor in 1 rounds, median $100M

What they do

Type
Growth equity (from a list, unverified)
Cheque size
Not stated
Based in
NEW YORK, United States
Cold pitches
Not stated

The record

Every round we can evidence, newest first3 appearances

  1. 2026

    1 round

  2. Aug
    Zealand PharmaDK · Firms' own news pages$100MLed
  3. 2025

    1 round

  4. Oct
    Kailera TherapeuticsSeries B · US · Crunchbase News$600MWith 9 others
  5. 2019

    1 round

  6. Nov
    EpizymeUS · FinSMEs$270MWith 1 other

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

What the register says

From the firm's own filings with the SEC, which it must file accurately by law

$40Bassets it manages, 3 advisers combinedOct 2026
Registeredinvestment adviserfull reporting to the SEC
Legal name
Royalty Pharma Manager, LLC
SEC number
CRD 334982

Recently backed

The latest companies Royalty Pharma put money into.

Zealand Pharma$100M · Aug 2026Kailera Therapeutics$600M · Oct 2025Epizyme$270M · Nov 2019

Quick answers about Royalty Pharma

What does Royalty Pharma invest in?

Royalty Pharma invests most often at Series B (100% of the rounds on record).

How active is Royalty Pharma?

3 investments on record, 1 of them in the last 12 months, and it led 1. The most recent was in Aug 2026.

What has Royalty Pharma invested in recently?

Its most recent investments on record: Zealand Pharma (Undisclosed round, Aug 2026), Kailera Therapeutics (Series B, Oct 2025) and Epizyme (Undisclosed round, Nov 2019).

How big are Royalty Pharma's cheques?

The median round it joins is $270M.

Is Royalty Pharma investing now?

Yes: it is actively investing, with 1 investments in the last 12 months.

What kind of investor is Royalty Pharma?

Royalty Pharma is a growth equity firm based in NEW YORK, United States.

How much does Royalty Pharma manage?

About $40B, as regulatory assets under management, 3 advisers added together (Oct 2026).

When was Royalty Pharma founded?

Royalty Pharma was founded in 1996.

Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Find similar investorsOpen your CRM

Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it